NASDAQ:AKBA

Akebia Therapeutics Stock Insider Trading

etoro logo Buy AKBA
*Your capital is at risk
$0.84
-0.0659 (-7.24%)
At Close: Aug 10, 2026

Akebia Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0.97. In total, the insiders bought 8.13M and sold 1.01M AKBA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
0.97
Buy 8.13M shares
Sell 1.01M shares
73% Buy Activity
Negligible or No Correlation
Sell Signal Low Confidence
Jun 29, 2026

Analysis Breakdown:

  • Weakened by a contradictory positive Insider Power Score.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Feb 02, 2026
Sell
Common Stock
S-Sale
Burke Steven Keith
SVP, Chief Medical Officer
Officer 25 375
Value: $35.3K
Feb 02, 2026
Sell
Common Stock
S-Sale
Burke Steven Keith
SVP, Chief Medical Officer
Officer 20 701
Value: $28.8K
Feb 02, 2026
Sell
Common Stock
S-Sale
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 16 846
Value: $23.4K
Feb 02, 2026
Sell
Common Stock
S-Sale
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 25 382
Value: $35.3K
Feb 02, 2026
Sell
Common Stock
S-Sale
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 27 544
Value: $38.3K
Feb 02, 2026
Sell
Common Stock
S-Sale
Ostrowski Erik
SVP, CFO, Cbo & Treasurer
C-Suite Officer 34 951
Value: $48.6K
Feb 02, 2026
Sell
Common Stock
S-Sale
Butler John P.
CEO And President
CEO / President 46 660
Value: $64.9K
Feb 02, 2026
Buy
Common Stock
A-Award
Butler John P.
CEO And President
CEO / President 175 250
Value: $247.1K
Feb 02, 2026
Sell
Common Stock
S-Sale
Butler John P.
CEO And President
CEO / President 96 065
Value: $133.5K
Jan 30, 2026
Buy
Common Stock
A-Award
Grund Nicholas
Chief Commercial Officer
Officer 204 000
Value: $287.6K
Jan 30, 2026
Buy
Stock Option (Right to buy)
A-Award
Grund Nicholas
Chief Commercial Officer
Officer 320 000
Value: $451.2K
Jan 30, 2026
Buy
Common Stock
A-Award
Burke Steven Keith
SVP, Chief Medical Officer
Officer 204 000
Value: $287.6K
Jan 30, 2026
Buy
Stock Option (Right to buy)
A-Award
Burke Steven Keith
SVP, Chief Medical Officer
Officer 320 000
Value: $451.2K
Jan 30, 2026
Buy
Common Stock
A-Award
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 190 000
Value: $267.9K
Jan 30, 2026
Buy
Stock Option (Right to buy)
A-Award
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 270 000
Value: $380.7K
Jan 30, 2026
Buy
Common Stock
A-Award
Malabre Richard C
SVP, Chief Accounting Officer
Officer 79 000
Value: $111.4K
Jan 30, 2026
Buy
Stock Option (Right to buy)
A-Award
Malabre Richard C
SVP, Chief Accounting Officer
Officer 119 000
Value: $167.8K
Jan 30, 2026
Buy
Common Stock
A-Award
Ostrowski Erik
SVP, CFO, Cbo & Treasurer
C-Suite Officer 204 000
Value: $287.6K
Jan 30, 2026
Buy
Stock Option (Right to buy)
A-Award
Ostrowski Erik
SVP, CFO, Cbo & Treasurer
C-Suite Officer 320 000
Value: $451.2K
Jan 30, 2026
Buy
Common Stock
A-Award
Butler John P.
CEO And President
CEO / President 743 000
Value: $1.05M
Jan 30, 2026
Buy
Stock Option (Right to buy)
A-Award
Butler John P.
CEO And President
CEO / President 1 115 000
Value: $1.57M
Jan 26, 2026
Buy
Employee Stock Option (right to buy)
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 165 600
Value: $104.3K
Jan 26, 2026
Buy
Employee Stock Option (right to buy)
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 27 900
Value: $60.3K
Jan 26, 2026
Buy
Common Stock
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 0
Value: $0
Jan 26, 2026
Buy
Common Stock
Rucci Carolyn M.
SVP, Chief Legal Officer
Officer 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT AKEBIA THERAPEUTICS
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...
GOLDEN STAR
Ticker Change Signal Date
GPOR
$158.45
6.03% Aug 06
FCX
$62.63
12.61% Jul 31
BIIB
$202.19
2.44% Jul 24
TSCO
$30.32
14.18% Jul 23
S
SW
$43.71
8.88% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE